Lv1
60 积分 2025-07-07 加入
Targeting YAP1 ‐Mediated Tubular Cell Senescence to Attenuate Maladaptive Repair and Fibrotic Transition After Acute Kidney Injury
11小时前
已关闭
Genotype-First Analysis in an Unselected Health System–Based Population and Phenotypic Severity of COL4A5 Variants
1个月前
已关闭
FKBP4-mediated reprogramming of H3K4bhb at energy metabolism ameliorates ischemic acute kidney injury
1个月前
已完结
Novel protein biomarkers for risk stratification and personalized medicine
1个月前
已完结
Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy
1个月前
已关闭
Atrasentan in Patients with IgA Nephropathy
1个月前
已完结
Renoprotective effects of sparsentan: clinical trial evidence in IgA nephropathy and FSGS
1个月前
已完结
Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD
1个月前
已完结
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
1个月前
已完结
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial
1个月前
已完结
皖公网安备34019202002308
